Frontier Biotechnologies Inc. (SHA:688221)

China · Delayed Price · Currency is CNY

14.06

+0.45 (3.31%)

At close: Oct 23, 2026

Market Cap	5.27B -4.4%
Revenue (ttm)	378.04M +175.8%
Net Income	-21.77M
EPS	-0.06
Shares Out	374.58M
PE Ratio	n/a
Forward PE	585.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,818,624
Open	13.36
Previous Close	13.61
Day's Range	12.79 - 14.15
52-Week Range	13.21 - 29.98
Beta	0.87
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2026

About Frontier Biotechnologies

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China. It offers Aikening, an IV fusion inhibitor for dual therapy of HIV-1. The company’s pipeline products include FB2004 indicated for HBV; FB7011 and FB7013 for IgA nephropathy; FB7012 to treat hyperuricemia and gout; FB7041 to treat tumors; FB7024 for the treatment of hyperlipidemia; FB7023 to treat ASCVD; FB7033 for the treatment of MASH; FB4001 for osteoporos... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2002

Employees 265

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688221

Full Company Profile

Financial Performance

In 2025, Frontier Biotechnologies's revenue was 123.39 million, a decrease of -4.70% compared to the previous year's 129.47 million. Losses were -268.05 million, 33.1% more than in 2024.

Financial Statements